Loading...
*  Sequence Similarity - 3VPX: Crystal structure of leucine dehydrogenase from a psychrophilic bacterium Sporosarcina...
3VPX: A psychrophilic leucine dehydrogenase from Sporosarcina psychrophila: Purification, characterization, gene sequencing and crystal structure analysis
  http://www.rcsb.org/pdb/explore/sequenceCluster.do?structureId=3VPX
*  NOVEL AMINO ACID DEHYDROGENASE, AND PROCESS FOR PRODUCING L-AMINO ACID, 2-OXO ACID OR D-AMINO ACID - Patent application
91368PRTRhodococcus qingshengii 1Met Ser Ile Asp Asp Glu Leu Arg Trp Asp Gly Glu Leu Thr Val Thr1 5 10 15Arg His Asp Arg Glu Thr Gly Thr Thr Phe Val Ile Arg Ile Asp Ser 20 25 30Thr Arg Leu Gly Pro Ala Ser Gly Gly Thr Arg Ala Ala His Tyr Pro 35 40 45Ser Ile Gly His Ala Leu Ala Asp Ala Gly Lys Leu Ala Gly Ala Met 50 55 60Thr Leu Lys Met Ala Val Ser Asp Leu Pro Met Gly Gly Gly Lys Ser65 70 75 80Val Ile Ala Leu Pro Ala Pro Arg Asn Gln Ile Asp Ala Ala Thr Trp 85 90 95Ser Arg Ile Leu Gly Ile His Ala Glu Asn Ile Asp Lys Leu Glu Gly 100 105 110Asn Tyr Trp Thr Gly Pro Asp Val Asn Thr Asn Ser Ser Asp Met Asp 115 120 125Gln Leu Ser Arg Thr Thr Arg Tyr Val Phe Gly Arg Ser Val Asp Lys 130 135 140Gly Gly Ala Gly Ser Ser Ala His Ala Thr Ala Leu Gly Val Phe Glu145 150 155 160Ala Met Lys Ala Thr Ala Arg Arg Arg Gly Leu Gly Thr Leu Asp Gly 165 170 175Arg Thr Val Leu Val Gln Gly Leu Gly Ala Val Gly Gly Asp Val Val 180 185 190Arg Leu Ala Ala Gln Ala Gly Ala Arg Leu Leu Val Ala Asp Thr Asp 195 200 205Pro Gln Arg Leu ...
  http://www.patentsencyclopedia.com/app/20110281309
*  RCSB PDB - 1BW9: PHENYLALANINE DEHYDROGENASE STRUCTURE IN TERNARY COMPLEX WITH NAD+ AND PHENYLPYRUVATE Literature...
1BW9: Phenylalanine dehydrogenase from Rhodococcus sp. M4: high-resolution X-ray analyses of inhibitory ternary complexes reveal key features in the oxidative deamination mechanism.
  http://www.rcsb.org/pdb/explore/litView.do?structureId=1BW9
*  Phosphorus acid - Wikipedia
Phosphorus oxoacids are oxoacids of phosphorus. Phosphorus exhibits oxidation states from +1 to +5. Oxygen may be in oxidation state -2 or -1, depending on whether a compound contains the peroxide group. There are a large number of such compounds, some of which cannot be isolated and are only known through their salts. Examples of phosphorus acids include: Phosphorus oxoacids containing P in oxidation state +1: H3PO2 (or H2PO(OH)), Hypophosphorous acid or phosphinic acid, a monoprotic acid Phosphorus oxoacids containing P in oxidation state +3: H3PO3 (or HPO(OH)2), Phosphorous acid or phosphonic acid, a diprotic acid Phosphorus oxoacids containing P in oxidation state +5 (see also phosphoric acids and phosphates): H3PO4 (or PO(OH)3), Phosphoric acid, a tribasic acid A similar compound is peroxomonophosphoric acid H3PO5 (or OP(OH)2(OOH)), a tribasic acid containing a peroxide group that replaces an oxygen atom in the hydroxyl group H4P2O7 (or (OH)2(O)P-O-P(O)(OH)2), Pyrophosphoric acid, a ...
  https://en.wikipedia.org/wiki/Phosphorus_acid
*  1gec - Proteopedia, life in 3D
Glycyl endopeptidase is a cysteine endopeptidase of the papain family, characterized by specificity for cleavage C-terminal to glycyl residues only and by resistance to inhibition by members of the cystatin family of cysteine proteinase inhibitors. Glycyl endopeptidase has been crystallized from high salt with a substrate-like inhibitor covalently bound to the catalytic Cys 25. The structure has been solved by molecular replacement with the structure of papain and refined at 2.1 A to an R factor of 0.196 (Rfree = 0.258) with good geometry. The structure of the S1 substrate binding site of glycyl endopeptidase differs from that of papain by the substitution of glycines at residues 23 and 65 in papain, with glutamic acid and arginine, respectively, in glycyl endopeptidase. The side chains of these residues form a barrier across the binding pocket, effectively excluding substrate residues with large side chains from the S1 subsite. The constriction of this subsite in glycyl endopeptidase explains ...
  http://proteopedia.org/wiki/index.php/1gec
*  Oxoacid - Wikipedia
An oxoacid is an acid that contains oxygen. Specifically, it is a compound that contains hydrogen, oxygen, and at least one other element, with at least one hydrogen atom bond to oxygen that can dissociate to produce the H+ cation and the anion of the acid. Generally, oxyacids are simply oxyanions attached to a positively-polarized hydrogen, which can be split off as a cation. Under Lavoisier's original theory, all acids contained oxygen, which was named from the Greek ὀξύς (oxys: acid, sharp) and the root -γενής (-genes: creator). It was later discovered that some acids, notably hydrochloric acid, did not contain oxygen and so acids were divided into oxoacids and these new hydroacids. All oxoacids have the acidic hydrogen bound to an oxygen atom, so bond strength (length) is not a factor, as it is with binary nonmetal hydrides. Rather, the electronegativity of the central atom (X) and the number of O atoms determine oxoacid acidity. With the same central atom X, acid strength ...
  https://en.wikipedia.org/wiki/Oxoacid
*  NES Profile: Chemistry (306)
Correct Response and Explanation (ShowHide) A. This question requires the examinee to demonstrate knowledge of the relationship between molecular structure and acid strength. The strength of an acid is a function of its tendency to ionize. For oxoacids with the same central atom, acid strength increases as the oxidation number of the central atom increases because of the resulting increase in polarity of the O-H bond. The oxidation number of nitrogen in HNO3 is +5 and in HNO2 it is +3, thus the O-H bond in HNO3 is more polar and ionizes more readily. ...
  http://www.west.nesinc.com/TestView.aspx?f=HTML_FRAG/NT306_Profile_CD4.html
*  Bagassosis -- Thermoactinomyces sacchari Symptoms, Diagnosis, Treatments and Causes - RightDiagnosis.com
Bagassosis - Thermoactinomyces sacchari information including symptoms, diagnosis, misdiagnosis, treatment, causes, patient stories, videos, forums, prevention, and prognosis.
  http://www.rightdiagnosis.com/b/bagassosis_thermoactinomyces_sacchari/intro.htm
*  Neuromics: Kinetic Assays and Stem Cell Toxicology Studies
Images and Figure: Images: Dose-Response curve for Co++ toxicity to Hoechst-stained hMSCs (UCB Derived catalog number SC00A1-HC). The bar graph on the lower right shows cell counts verses [Co++] at 24, 48 & 72 hours exposure to Co++. Results at 144 hours showed massive cell death. The initial increase in cell counts at low concentration may reflect the well-known activation of HIFs by Co++. Counts were determined by Hoechst-stained MSCs and simultaneous propidium iodide staining shows increasing numbers of permeable (presumably dead) cells at 24, 48 & 72 hours post-Co++ during exposure to 10% DMSO. Images acquired on Biotek Cytation 3 imaging system. ...
  http://neuromics.blogspot.com/2014/02/kinetic-assays-and-stem-cell-toxicology.html
*  Patent US6147109 - Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA ... - Google Patents
A new use for HMG-CoA reductase inhibitors is provided. In the instant invention, HMG-CoA reductase inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity through a mechanism other than preventing the formation of oxidative-LDL. As a result, HMG-CoA reductase inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
  http://www.google.com/patents/US6147109?dq=%22robert+sheehan%22
*  Patent US6180597 - Upregulation of Type III endothelial cell nitric oxide synthase by rho ... - Google Patents
A use for rho GTPase function inhibitors is provided. In the instant invention, rho GTPase function inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, rho GTPase function inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but do not necessarily exclude hyperlipidemics and hypercholesterolemics.
  http://www.google.ca/patents/US6180597
*  Patent US8318501 - Methods for assaying percentage of glycated hemoglobin - Google Patents
The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.
  http://www.google.com.au/patents/US8318501
*  Recombinant human D Amino Acid Oxidase protein (ab86700)
Buy our Recombinant human D Amino Acid Oxidase protein. Ab86700 is a full length protein produced in Escherichia coli and has been validated in SDS-PAGE. Abcam…
  http://www.abcam.com/recombinant-human-d-amino-acid-oxidase-protein-ab86700.html
*  Gentaur Molecular :BioBasic \ L Amino acid oxidase >4 U mg \...
Gentaur molecular products has all kinds of products like :search , BioBasic \ L_Amino acid oxidase >4 U_mg \ ALS002764 for more molecular products just contact us
  http://www.antibody-antibodies.com/product_det.php?id=161686&supplier=search&name=L_Amino%20acid%20oxidase%20%20%3E4%20U_mg
*  重组人D Amino Acid Oxidase蛋白(ab117193)|Abcam中国
购买我们的重组人D Amino Acid Oxidase蛋白。Ab117193为全长蛋白,在大肠杆菌中生产并经过SDS-PAGE实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。
  http://www.abcam.cn/recombinant-human-d-amino-acid-oxidase-protein-ab117193.html
*  LOXL1 Polymorphism in Pseudoexfoliation Syndrome - Full Text View - ClinicalTrials.gov
To evaluate the association profiles of the lysyl oxidase-like 1 gene polymorphisms with pseudoexfoliation syndrome in the Korean population, peripheral blood sampling will be done from the patients with pseudoexfoliation.. And genotypes of the three single nucleotide polymorphisms of lysyl oxidase-like 1 gene , rs1048661, rs3825942, rs2165241 were analyzed by direct sequencing. ...
  https://clinicaltrials.gov/ct2/show/NCT01515735
*  Purification and properties of D-aspartate oxidase from Crypto...
Purification and properties of D-aspartate oxidase from Cryptococcus humicolus UJ1.: D-Aspartate oxidase (EC 1.4.3.1), which is highly specific to D-aspartate,
  https://www.mysciencework.com/publication/show/purification-properties-d-aspartate-oxidase-from-cryptococcus-humicolus-uj1-ceb8314b
*  The active site and substrate-binding mode of 1-aminocyclopropane-1-carboxylate oxidase determined by site-directed mutagenesis...
The active site and substrate-binding mode of MD-ACO1 (Malus domestica Borkh. 1-aminocyclopropane-1-carboxylate oxidase) have been determined using site-directed mutagenesis and comparative modelling methods. The MD-ACO1 protein folds into a compact jelly-roll motif comprised of eight α-helices, 12 β-strands and several long loops. The active site is well defined as a wide cleft near the C-terminus. The co-substrate ascorbate is located in cofactor Fe2+-binding pocket, the so-called '2-His-1-carboxylate facial triad'. In addition, our results reveal that Arg244 and Ser246 are involved in generating the reaction product during enzyme catalysis. The structure agrees well with the biochemical and site-directed mutagenesis results. The three-dimensional structure together with the steady-state kinetics of both the wild-type and mutant MD-ACO1 proteins reveal how the substrate specificity of MD-ACO1 is involved in the catalytic mechanism, providing insights into understanding the ...
  http://www.biochemj.org/content/380/2/339
*  Glycine Oxidase H244K, Bacillus subtilis recombinant protein - Glycine oxidase, glycine oxygen oxidoreductase (deaminating), GO...
Glycine Oxidase H244K, Bacillus subtilis recombinant protein, Glycine oxidase, glycine oxygen oxidoreductase (deaminating), GO validated in (PBV11404r-250), Abgent
  http://www.abgent.com/products/PBV11404r-Glycine-Oxidase-H244K-Bacillus-subtilis-recombinant-protein
*  Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast...
Basal-like breast carcinoma is characterized by the expression of basal/myoepithelial markers, undifferentiated phenotype, highly aggressive behaviour and frequent triple negative status (ESR-, PR-, Her2neu-). We have previously shown that epithelial-mesenchymal transition (EMT) occurs in basal-like breast tumours and identified Lysyl-oxidase-like 2 (LOXL2) as an EMT player and poor prognosis marker in squamous cell carcinomas. We now show that LOXL2 mRNA is overexpressed in basal-like human breast carcinomas. Breast carcinoma cell lines with basal-like phenotype show a specific cytoplasmic/perinuclear LOXL2 expression, and this subcellular distribution is significantly associated with distant metastatic incidence in basal-like breast carcinomas. LOXL2 silencing in basal-like carcinoma cells induces a mesenchymal-epithelial transition (MET) associated with a decrease of tumourigenicity and suppression of metastatic potential. Mechanistic studies indicate that LOXL2 maintains the mesenchymal ...
  http://www.mdanderson.es/publicaciones/lysyl-oxidase-2-loxl2-new-regulator-cell-polarity-required-metastatic-dissemination-ba
*  PATCH 13/25] xfs: factor dir2 block read operations
From: Dave Chinner ,dchinner@xxxxxxxxxx, In preparation for verifying dir2 block format buffers, factor the read operations out of the block operations (lookup, addname, getdents) and some of the additional logic to make it easier to understand an dmodify the code. Signed-off-by: Dave Chinner ,dchinner@xxxxxxxxxx, --- fs/xfs/xfs_dir2_block.c , 386 +++++++++++++++++++++++++---------------------- 1 file changed, 209 insertions(+), 177 deletions(-) diff --git a/fs/xfs/xfs_dir2_block.c b/fs/xfs/xfs_dir2_block.c index 53666ca..25ce409 100644 --- a/fs/xfs/xfs_dir2_block.c +++ b/fs/xfs/xfs_dir2_block.c @@ -56,6 +56,178 @@ xfs_dir_startup(void) xfs_dir_hash_dotdot = xfs_da_hashname((unsigned char *)'..', 2); } +static int +xfs_dir2_block_read( + struct xfs_trans *tp, + struct xfs_inode *dp, + struct xfs_buf **bpp) +{ + struct xfs_mount *mp = dp-,i_mount; + + return xfs_da_read_buf(tp, dp, mp-,m_dirdatablk, -1, bpp, + XFS_DATA_FORK, NULL); +} + +static void +xfs_dir2_block_need_space( + struct ...
  http://oss.sgi.com/archives/xfs/2012-10/msg00500.html
*  A dual-cell device designed as an oxidase mimic and its use for the study of oxidase-like nanozymes - Chemical Communications ...
A dual-cell device has been designed as an oxidase-like mimic with the oxidation of 3,3′,5,5′-tetramethylbenzidine as a model reaction. This dual-cell device could be also used to study oxidase-like nanozymes. It was found that only the catalytic sites for oxygen reduction are essential and necessary for oxidase-li
  http://pubs.rsc.org/en/content/articlelanding/2018/cc/c7cc08992a
*  Industrial Example 6: Amino Acid Oxidases - University of Manchester | Coursera
Video created by University of Manchester for the course 'Industrial Biotechnology'. This module looks at the production of pharmaceuticals and fine chemicals using biocatalysis. Specifically, we will look at isolated biocatalytic ...
  https://tr.coursera.org/learn/industrial-biotech/lecture/y4YwX/industrial-example-6-amino-acid-oxidases
*  PATCH 2/2] xfs: check min blks for random debug mode sparse allocations
The inode allocator enables random sparse inode chunk allocations in DEBUG mode to facilitate testing. Sparse inode allocations are not always possible, however, depending on the fs geometry. For example, there is no possibility for a sparse inode allocation on filesystems where the block size is large enough to fit one or more inode chunks within a single block. Fix up the DEBUG mode sparse inode allocation logic to trigger random sparse allocations only when the geometry of the fs allows it. Signed-off-by: Brian Foster ,bfoster@xxxxxxxxxx, --- fs/xfs/libxfs/xfs_ialloc.c , 15 ++++++++------- 1 file changed, 8 insertions(+), 7 deletions(-) diff --git a/fs/xfs/libxfs/xfs_ialloc.c b/fs/xfs/libxfs/xfs_ialloc.c index a18bc75..66efc70 100644 --- a/fs/xfs/libxfs/xfs_ialloc.c +++ b/fs/xfs/libxfs/xfs_ialloc.c @@ -606,20 +606,20 @@ xfs_ialloc_ag_alloc( uint16_t allocmask = (uint16_t) -1; /* init. to full chunk */ struct xfs_inobt_rec_incore rec; struct xfs_perag *pag; - int do_sparse = 0; -#ifdef DEBUG - ...
  http://oss.sgi.com/archives/xfs/2015-06/msg00007.html